In the last 3 years, 14 children with high-risk leukemia (11 ALL, 2 AML and 1 CML) underwent cord blood transplantation from unrelated HLA-mismatched donors at a median of 99 days from the start of search. Eight patients were transplanted in second CR, one in accelerated phase, three at relapse and two patients in first CR. Conditioning regimen (fractionated TBI, etoposide, CY and anti-lymphocyte serum) and prophylaxis of GVHD (CsA and 6-methylprednisolone) were identical for all patients. Neutrophils > 0.5 ؋ 10 9 /l were reached at a median of 33 days from transplant, but in four cases we observed an autologous hematopoietic reconstitution (three spontaneous, one after autologous BM rescue). Acute and chronic GVHD were observed in 10/14 and 3/8 evaluable cases, respectively. Three patients died of transplant-related toxicity and three patients relapsed. The probabilities of event-free, disease-free and overall survival were 50, 53 and 64%, respectively. Cord blood transplant from HLA-mismatched unrelated donor is a valid option for the treatment of children with high-risk leukemia. With our eligibility criteria, conditioning regimen and prophylaxis of graft-versus-host disease, the main obstacles to successful transplant were represented by graft failure and fatal acute GVHD.
many studies suggested that the UCB could be employed for transplantation, 2 and finally the first UCB transplant was successfully performed in a patient with Fanconi anemia in 1988. 3 The indication for a UCB transplant extended rapidly from patients with an HLA-matched or -mismatched sibling donor 4 to candidates for transplantation from unrelated donors. [5] [6] [7] As an alternative to international bone marrow donor registries, the expansion of UCB banks both in Europe and in North America opened new perspectives of transplantation for a significant proportion of leukemic patients lacking an HLA-matched related donor. [8] [9] [10] Therefore since April 1995 we adopted a policy of searching stem cell sources in UCB banks for patients with high risk leukemia. So far, 14 patients prepared with an identical regimen of conditioning and GVHD prophylaxis have been submitted to an HLA-mismatched unrelated UCB transplant. Five of these patients (UPN 300, UPN 312, UPN 324, UPN 325 and UPN 337) were included in the previously reported European retrospective study. 7 Our experience indicates that UCB transplant may be rapidly and successfully performed in a significant proportion of high-risk leukemia patients.
Patients and methods

Patient eligibility and donor selection
Our study on UCB transplantation for the treatment of patients younger than 50 years with high-risk leukemia lacking an HLA-identical related donor was approved by the Institutional Review Board of the Department of Cellular Biotechnologies and Hematology of the University 'La Sapienza' of Rome. Patients with either ALL or AML in second or subsequent CR or in relapse with Ͻ30% of blasts in the BM aspirate and patients with CML in accelerated phase (AP) were considered to be at high-risk of disease progression. Patients with acute leukemia in first CR were also included in the high-risk category if they had one or more of the following features: ALL with t(9;22) or translocations involving chromosome band 11q23 and molecular evidence of persistent leukemia 3 or more months after CR, failure to achieve CR with primary induction regimen or diagnosis of AML occurring after a myelodysplastic syndrome. At the same time all high-risk patients entered our program of search for an HLA-matched unrelated BM donor, which was performed in the Bone Marrow Donor Worldwide Registry through the Italian Bone Marrow Donor Registry. Informed consent and autologous back-up BM were also required before UCB transplant.
From April 1995 to November 1997, searches were simultaneously conducted on behalf of 63 patients with highrisk leukemia at the Placental Blood Programs of New York, Milan, Düsseldorf and Paris Cord Blood Banks. These patients had a median age of 11 years (range 1-49) and a median body weight of 42 kg (range 10-107). Fortysix of them were children (age р16 years) and 17 adults. Our objective was to find a UCB unit containing at least 1.5 × 10 7 nucleated cells/kg body weight of the recipient and sharing at least four HLA loci with the recipient after DRB1 high resolution typing. After identification of a suitable UCB unit, confirmatory HLA typing of the patient and the prospective unit was performed. At least one UCB unit fulfilling these criteria was identified for 30 candidates at a median time of 37 days (range 2-449) from the start of search. All these 30 patients had at least one available BM donor in the preliminary interrogation of the Bone Marrow Donor Worldwide Registry. In patients with an eligible UCB unit and stable disease during search, we preferred to continue BM search until the definition of an HLA-matched BM donor, otherwise UCB transplant was chosen. At the time of this report, 14 UCB transplants had been performed and two were underway. In 14 patients UCB transplant was not performed: six lost eligibility because of resistant progressive disease during the search, four patients refused UCB transplant and in four patients we preferred to transplant BM from unrelated donors.
All transplanted units were negative for HIV, hepatitis B and C, and absence of CMV infection was confirmed by antigenemia assay. Active CMV infection of the donor's mother was excluded by the absence of IgM antibody to CMV.
Transplantation procedure
The cryopreserved UCB unit was shipped to our Institution in an appropriate container cooled by liquid nitrogen in vapor phase and stored in liquid nitrogen. The unit was thawed in the laboratory and washed with 10% dextran and 5% albumin before infusion, according to previously published methods.
11 Post-thawing cellular viability was assessed by Trypan blue-dye exclusion. To evaluate the proliferative potential of transplanted UCB units, both immunocytometric analysis for CD34+ve cells and clonogenic assay for CFU-GM were performed soon after thawing.
All patients were prepared with an identical conditioning regimen consisting of fractionated TBI (200 cGy twice a day for six doses given over 3 consecutive days starting on day −7), etoposide (20 mg/kg by continuous i.v. infusion over 24 h on day −4), CY (60 mg/kg, once daily i.v. on days −3 and −2, total dose 120 mg/kg) and anti-lymphocyte serum (600 IU/kg once daily by i.v. infusion over 16 h for 4 consecutive days starting on day −6, total four doses).
All patients were kept in reverse isolation under highenergy particulate air filtration. A parent roomed with each patient. Prophylactic measures for fungal, viral and bacterial infections consisted of daily administration of fluconazole, acyclovir and ciprofloxacin. Ganciclovir (5 mg/kg twice daily i.v.) or foscarnet (180 mg/kg by continuous i.v. infusion over 24 h) were given as pre-emptive therapy in patients with positive CMV antigenemia.
BM aspirate was performed in patients who did not reach neutrophil counts Ͼ0.2 × 10 9 /l by day +25. If marrow cellularity was Ͼ5% with representation of at least two hemopoietic lineages, the patients were eligible for daily administration of G-CSF at the dose of 5 g/kg. Reinfusion of autologous back-up cryopreserved marrow was allowed in severely neutropenic patients with Ͻ5% marrow cellularity at day +25 or failing to reach a sustained neutrophil counts Ͼ0.5 × 10 9 /l after 10 days therapy with G-CSF.
Chimerism and engraftment
Chimerism was evaluated by studying DNA polymorphism, detected by PCR amplification of VNTR regions, that was performed on BM and peripheral blood cells at day 20, 35, 60, 100, 180, 270 and 365 after transplantation. Complete chimerism required all cells in the recipients to be of donor origin, while the simultaneous presence of donor and recipient cells was defined as mixed chimerism. Peripheral blood counts were performed daily and time to engraftment was defined as the first of 3 consecutive days with у0.5 × 10 9 /l neutrophils of donor origin.
GVHD prophylaxis and treatment
All patients received a daily administration of CsA (3 mg/kg) starting at day −1 and 6-methyl-prednisolone (6MP) (2 mg/kg from day −6 to day 0 and 1 mg/kg thereafter). The dose of 6-MP was tapered from day +30 and full dose CsA was given until day +50 and then tapered 5% per week. Acute GVHD, which was scored by standard criteria, 12 was initially treated by increasing doses of 6-MP (3 to 10 mg/kg).
Statistics
Event-free survival (EFS) was defined as the time from transplantation to graft failure, leukemia relapse, death or to the last observation. Disease-free survival (DFS) was defined as the time from transplantation to leukemia relapse, death or to the last observation. Survival was calculated either from transplantation to death or to the last observation. Actuarial EFS, DFS and survival curves were prepared according to the Kaplan-Meier method. 13 
Results
UCB units and patient characteristics
Some features of transplanted UCB units, some patient characteristics, donor/recipient combinations and tests performed after thawing of UCB units are illustrated in Table  1 . We transplanted children with UCB units mismatched with the recipient for 1 (n = 12) or 2 HLA loci (n = 2). Five UCB transplants were sex-mismatched and eight pairs were major (n = 7) or minor (n = 1) ABO mismatched. Half of UPN = unique patient number; BW = body weight; CFU-GM = colony-forming unit granulocyte-macrophage; F = female; M = male; RBC-D = red blood cell depleted; WB = whole blood; NC = nucleated cells; UCB = umbilical cord blood; s.d. = standard deviation. a After serologic AB and high-resolution molecular typing of DRB1 (recipient is underlined). b Expressed as total colony-forming units.
the patients were previously infected by CMV. The recovery of viable nucleated cells was higher for 'whole blood' units.
Other features of the consecutive 14 patients transplanted between August 1995 and December 1997 are described in Table 2 . Eleven patients had ALL, 2 AML and 1 CML in AP. Disease status changed in seven patients (four relapsed and three achieved CR) before the completion of search procedures. Overall, at time of UCB transplant, two patients were in first CR, eight were in second CR and three were transplanted in relapse occurring shortly after second CR. Median duration of first CR was 13 months in the eight patients transplanted in second CR. Patients with acute leukemia transplanted in CR did so at a median of 100 days from their last CR. Overall, UCB transplants were performed at a median time of 99 days from the start of the search and at a median of 52 days from the formal identification of the eligible UCB unit. The longer delays were associated with the prolonged time required for some patients to achieve full eligibility to the UCB transplant procedure.
Engraftment and chimerism
All patients achieved neutrophil counts у0.5 × 10 9 /l at a median of 33 days (range 22-74) after UCB transplant. Four patients received daily G-CSF therapy since they had not reached neutrophil counts Ͼ0.2 × 10 9 /l by day +25. Three of them responded (UPN 312, UPN 337 and UPN 381), while UPN 300 was reinfused with autologous cryopreserved marrow at day +58 and recovered with autologous neutrophils at day +74. The study of DNA polymorphism, detected by PCR amplification of VNTR regions at time of myeloid engraftment, showed complete chimerism in 10 patients. The remaining four patients showed an autologous hemopoietic reconstitution which, in three of them (UPN 312, UPN 341 and UPN 375), occurred spontaneously at day +37, +33 and +27, respectively.
Nine patients recovered Ͼ20 × 10 9 /l platelets at a median of 66 days (range 17-135). Platelet counts of 50 × 10 9 /l and 100 × 10 9 /l were reached at a median of 91 and 130 days, respectively. RBC transfusions could be stopped in eight of the nine patients who were alive and disease-free at day +100, after a median of 81 days (range, . In UPN 375, we performed DNA polymorphism studies on separate cell populations (ie PMN vs non-adherent mononuclear cells) from peripheral blood samples at day +24, +36 and +56. These studies demonstrated that spontaneous autologous myelopoiesis occurred in this patient in the presence of a small proportion of circulating lymphocytes of donor origin. At that time this patient was on CsA which was abruptly interrupted 3 weeks later because of molecular evidence of autologous myelopoiesis, recovery of neutrophils Ͼ0.5 × 10 9 /l and no clinical signs of acute GVHD. However, after CsA discontinuation, an increased proportion of donor circulating lymphocytes was detected and the patient developed acute GVHD refractory to therapy which rapidly progressed to fatal grade IV GVHD.
GVHD
Among the 10 patients who engrafted, acute GVHD occurred in eight patients at a median of 11 days from UCB transplant (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . It was of grade I involving only the skin in five, while we observed a more aggressive course of the disease in the remaining three cases with two having grade II acute GVHD and 1 grade III. Among the patients in whom the donor hemopoietic cells failed to engraft, two developed acute GVHD, respectively at day +14 with grade II (UPN 300) and at day +51 with grade IV (UPN 375).
All eight patients developing grade I-II acute GVHD responded to high-dose 6-MP, while two patients with grade III-IV disease died of progressive and refractory GVHD. Three of the eight evaluable patients developed chronic GVHD, which was limited in one and extensive in two, occurring respectively at 7, 4 and 3.5 months after transplantation.
Outcome
As of August 1998, after a median follow-up of 18 months, nine patients were alive and five died. The overall survival curve projects 64% of our transplanted patients at 3 years (Figure 1) . Three patients died of transplant-related causes (two acute GVHD and one septic death) and two, transplanted in relapse, died with progressive leukemia. The means of Karnofsky scores for patients alive at 4, 8 and 12 months after UCB transplant were 85%, 94% and 96%, respectively.
Eight patients are alive and disease-free 10 to 37 months after UCB transplant, three relapsed and three died in CR (Table 2) , with an actuarial DFS probability of 53% at 3 years ( Figure 1) . Stable engraftment was demonstrated in seven of the eight patients still surviving disease-free by the detection of a complete chimerism in all controls performed after UCB transplant. The remaining patient transplanted for AML in second CR (UPN 300), who failed to engraft, is alive and disease-free 35 months after reinfusion of his PCR-negative marrow. Because of four graft failures, one relapse and two deaths in CR, 50% of our patients are projected for event-free survival at 2.5 years (Figure 1) .
Discussion
In the last 3 years, we intended to perform UCB transplant from unrelated donors in leukemic patients with high-risk features who lacked an HLA-matched related donor. In fact, the short duration of responses in such patients fosters the use of immediately available, cryopreserved UCB over BM from unrelated donor. In our experience, which included DRB1 high-resolution typing, no patient found HLA-matched units. It has been reported that transplants have been successfully performed with UCB units from unrelated mismatched donors after serologic class I HLA antigens and either low or high resolution DRB1 typing. Therefore, considering eligible UCB units with 1 or 2-HLA locus disparity and adequate cellularity, 30 of our 63 patients could have been transplanted shortly after the start of the search. The decreased time of search should be considered as a potential factor negatively influencing the outcome of patients transplanted with UCB. In this context, UCB transplants from unrelated donors should be more properly compared with BMT from rapidly available donors such as haploidentical family members. 14, 15 Graft failure and autologous hemopoietic reconstitution have been associated with the non-myelosuppressive conditioning regimens in transplants for non-malignant diseases 16, 17 or to T cell depletion in transplants for patients with malignant conditions. 18, 19 The low numbers in our patient series limits our ability to understand why, despite the quite intensive conditioning regimen, we observed an early spontaneous autologous hemopoietic reconstitution in three of our 14 transplanted cases. Indeed, there may be a functional T cell depletion in cord blood that contributes to the higher rate of graft failure and spontaneous autologous hemopoietic reconstitution in our UCB recipients. We also would like to remark that G-CSF was not given early after UCB transplant in our study. Regardless of the different conditioning regimens employed, G-CSF was administered daily from day 0 in a patient series with only one of 25 cases developing a spontaneous autologous reconstitution. 5 Therefore, it might also be possible that driving cord blood stem cells with G-CSF early after transplant reduces the emergence of autologous hemopoiesis. Moreover, hemopoietic growth factors could be prospectively evaluated to accelerate the recovery of neutrophils, platelets and RBC which appeared, also in our small series, significantly delayed after cord blood transplant. 6, 7 In the absence of spontaneous autologous reconstitution, graft failure occurred in one of our patients who was salvaged by the reinfusion of cryopreserved autologous marrow. Autologous BM harvest remains therefore mandatory before UCB transplant.
Our regimen of GVHD prophylaxis included CsA and 6-MP at standard doses, fearing negative effects on engraftment of additional MTX. As reported in other retrospective studies of UCB transplants from unrelated HLAmismatched donors, we observed grade II-IV acute GVHD in approximately one-third of cases, which appears significantly lower than that observed in children receiving unrelated BMT for similar conditions. 20 However, we must acknowledge that a more intensive GVHD prophylactic regimen, including T cell depletion, may significantly reduce the incidence of severe GVHD after unrelated BMT. 21 One of our fatal episodes of acute GVHD suggests that CsA treatment should not be abruptly interrupted in patients with purely autologous myelopoiesis, since even a small proportion of persisting donor lymphocytes may trigger acute GVHD. A low rate of chronic GVHD should be expected in UCB transplants from unrelated donors 6, 7 and our observation of chronic GVHD in three of eight evaluable patients, should be confirmed in a larger group of cases.
Since too few patients were treated, the GVL effect may be only suggested by the low relapse rate observed in our ALL patients transplanted in second or subsequent CR. In fact, durable responses are expected in less than 10% of such patients treated with intensive chemotherapy and ABMT followed or not by immunomodulating regimens with recombinant IL-2. 22, 23 Moreover, recurrent leukemia observed in patients in relapse at the time of transplant suggests modification of our eligibility criteria to exclude such patients from up-front UCB transplants.
EFS, DFS and overall survival in our series, which also includes three patients in relapse, were respectively 50%, 53% and 64%, more than 2 years from UCB transplant. These results compare favorably with those experienced by other groups in children transplanted from an unrelated BM donor. Indeed, the Seattle transplant team reported a 3-year DFS of 47% for 16 good-risk patients receiving an unmanipulated HLA-mismatched transplant, 20 while the Milwaukee group, using a very intensive conditioning regimen and a limited degree of T cell depletion in association with the post-transplant immunosuppression for GVHD prophylaxis, obtained a 3-5-year EFS of 43% for children partially HLA-mismatched with their unrelated marrow donors. 21 We conclude that UCB transplant should be considered as an alternative to unrelated BMT, since it can be offered in a short time to a significant proportion of patients with high-risk leukemia lacking an HLA-matched family donor. In order to improve the results, all efforts should be made to design appropriate prospective cooperative trials with the main objective of reducing the proportion of graft failure evaluated by sensitive molecular methods, accelerating hemopoietic recovery and ameliorating GVHD control.
